Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
J Med Virol
; 93(2): 775-785, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-1196401
ABSTRACT
Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI] 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR 1.36; 95% CI 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR 3.88; 95% CI 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine Monophosphate
/
Adrenal Cortex Hormones
/
Ritonavir
/
Alanine
/
Lopinavir
/
Antibodies, Monoclonal, Humanized
/
COVID-19
/
Hydroxychloroquine
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Med Virol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS